Emergent BioSolutions

GAITHERSBURG, MD · CIK 0001367644 · Biotech · Public

Anthrax and mpox vaccines, and opioid overdose reversal therapeutics

emergentbiosolutions.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$48M
1 Form D · Oct 2018
95 months since last filing
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$47,870,412
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2497b3 bio, inc.—$5.7M
2498DUET BIOSYSTEMS, INC——
2499Trex Bio——
2500Emergent BioSolutions—$48M
2501ARTELO BIOSCIENCES, INC.—$33M
2502Celmatix Inc.—$20M
2503Exciva——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Daniel Abdun-NabiDirector · Executive Officer
  • Sue BaileyDirector
  • Fuad El-HibriDirector · Executive Officer
  • Zsolt HarsanyiDirector
  • Jerome HauerDirector
  • Adam HaveyExecutive Officer
  • George JoulwanDirector
  • Robert KramerExecutive Officer
  • Richard LindahlExecutive Officer
  • Ronald RichardDirector
  • Atul SaranExecutive Officer
  • Katherine StreiExecutive Officer
  • Louis SullivanDirector
  • Kathryn ZoonDirector

Patents

USPTO · 0 granted of 6
  • 2-PYRIDONE Antimicrobial Compositionsapplication
  • Stable Anthrax Vaccine Formulationsapplication
  • Use Of E. Coli Surface Antigen 3 Sequences For The Export Of Heterologous Antigensapplication
  • Vaccines Against Clostridium Difficile And Methods Of Useapplication
  • Stable Anthrax Vaccine Formulationsapplication
  • Novel 2-HETEROARYLOXY-PHENOL Derivatives As Antibacterial Agentsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.